TOP2A and cancer: Although TopIIα expression and its implication for TopII inhibitors have been extensively investigated in several cancers, especially in breast cancer, few reports have described TopIIα expression and its cross resistance to other cytotoxic drugs in NSCLC [10,11,14-16].